睑板腺癌术后辅助放疗的疗效观察  

Review the efficacy of postoperative adjuvant radiotherapy with meibomian adenocarcinoma

作　　者：杜珂[1] 张琦[1] 

机构地区：[1]华中科技大学同济医学院附属襄樊医院肿瘤科,湖北省襄樊441021

出　　处：《临床眼科杂志》2010年第6期518-520,共3页Journal of Clinical Ophthalmology

摘　　要：目的评价术后放疗在治疗睑板腺癌中的疗效及不良反应。方法将26例(26只眼)睑板腺癌患者分为两组,16例患者采用手术加术后放疗治疗,10例患者只采用单纯手术治疗。结果术后辅助放疗组无疾病进展生存期为62.5%%,单纯手术组为20%,差异有统计学意义(P<0.05);术后辅助放疗总生存期为81.3%,单纯手术组为80%,组间疗效比较差异无统计学意义(P>0.05)。结论手术治疗是睑板腺癌的首选治疗方法,术后补充放疗可降低局部肿瘤复发率,延长无疾病进展生存期。Objective To evaluate the efficacy and adverse reactions of postoperative radiotherapy in the treatment of meibomian adenocarcinoma. Methods The 26 meibomian adenocarcinoma patients were divided into two groups,16 patients were treated with surgery and postoperative radiotherapy,10 patients were just only treated with surgery. Results The progression-free survival of additional radiotherapy group was 62.5%,and the surgery group was 20%,the difference was statistically significant （P0.05）; Overall survival after radiotherapy was 81.3%,surgery group was 80%,the difference between the two groups was not statistically significant （P0.05）.Conclusion Surgery is the preferred treatment for the meibomian adenocarcinoma,and additional radiotherapy after surgery could reduce the local recurrence rate of tumour and prolong the duration of progression-free disease.

关 键 词：睑板腺癌 术后放疗 复发率 

分 类 号：R739.7[医药卫生—肿瘤]